OTR Global downgrades iQIYI (NASDAQ:IQ) from Mixed to Negative.
ADC Therapeutics Highlights Presentation Of Updated ZYNLONTA Clinical Data At 16th Annual International Conference On Malignant Lymphoma
LOTIS-2 updated results demonstrate durable responses of ZYNLONTA™ with median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCL
LOTIS-3 updated Phase 1